Nkarta Inc(NKTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 9 at 4:01 PM ET (Korea 10/10 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.58 | Insider Own | 19.62% | Shs Outstand | 71.6M | Perf Week | -12.62% |
| Market Cap | 0.16B | Forward P/E | - | EPS next Y | 9.09% | Insider Trans | -0.01% | Shs Float | 57.6M | Perf Month | -19.93% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.4 | Inst Own | 64.21% | Short Float | 6.36% | Perf Quarter | -19.35% |
| Income | -0.12B | P/S | - | EPS this Y | -18.32% | Inst Trans | 2.53% | Short Ratio | 5.91 | Perf Half Y | 3.69% |
| Sales | 0.00B | P/B | 0.65 | EPS next 5Y | 1.82% | ROA | -29.86% | Short Interest | 3.66M | Perf YTD | 21.62% |
| Book/sh | 3.46 | P/C | 0.88 | EPS past 3/5Y | 18.61% 23.69% | ROE | -38.76% | 52W High | -39.52% ($3.72) | Perf Year | -4.66% |
| Cash/sh | 2.55 | P/FCF | - | Sales past 3/5Y | - | ROIC | -37.36% | 52W Low | 32.35% ($1.70) | Perf 3Y | 63.04% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -6.7% | Gross Margin | - | Volatility(W/M) | 6.44% 6.44% | Perf 5Y | -87.57% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.98 | EPS Q/Q | -74.47% | Profit Margin | - | RSI (14) | 32.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.98 | Sales Q/Q | - | SMA20 | -15.29% ($2.66) | Beta | 1.18 | Target Price | $10.83 |
| Payout | - | Debt/Eq | 0.3 | Earnings | 2026/8/10 | SMA50 | -13.48% ($2.6) | Rel Volume | 1.46 | Prev Close | $2.22 |
| Employees | 108 | LT Debt/Eq | 0.27 | EPS/Sales Surpr. | -49.88% - | SMA200 | -11.56% ($2.54) | Avg Volume(3M) | 0.62M | Price | $2.25 |
| IPO | 2020/7/10 | Option/Short | Yes/Yes | Trades | 3178 | Volume | 904,871 | Change | 1.35% |
🧬 Nkarta is a clinical-stage biotech company, traded under the ticker NKTX, that develops off-the-shelf natural killer (NK) cell therapies. By combining a cell expansion and cryopreservation platform with its proprietary cell engineering technology, the company is developing next-generation immune cell therapies in the autoimmune disease space that can be standardized and administered without the need for patient-specific harvesting.
Over the past 1 year, roughly in the middle
40% below its 1-year high.
Traded more than usual That is 146% of its average volume.
NKTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -18.3% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.6%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 64.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #328 of 593 in the industry
Based on market cap of $161M.
FAQ
What kind of company is NKTX?
NKTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NKTX?
The market cap of NKTX is approximately $161M, ranking 4,246 within its sector.
What is the 52-week high and low for NKTX?
NKTX has recorded a 52-week high of $3.72 and a low of $1.70.
